Genes, Environment and Multi-Omics Maps Reshape How IPF Is Understood and Predicted

Idiopathic pulmonary fibrosis, a progressive and scarring form of interstitial pneumonia whose cause remains unclear, is being reframed by a sweeping review published in the journal Genes and Environment. Rather than cataloguing single genes or pathways, the review assembles genetic variation maps, multi-omics regulatory networks and environmental exposure effects into one framework that runs from genetic discovery to prognostic assessment, and it proposes a multi-gene risk score, or MGRS, to predict outcomes and guide targeted treatment design.

The clinical stakes are considerable. Epidemiological data from 2023 show North America with the highest incidence and prevalence of IPF, at 9.0 and 27.2 per 100,000 population, roughly double the figures for Europe (5.1 and 14.6) and Asia (4.4 and 14.8). The disease is closely tied to age, particularly affecting men over 60, with an average age at diagnosis of about 66 years. Males account for roughly 70 percent of cases and fare worse, with mortality in the United States 1.63 times higher than in females. Antifibrotic therapy use is also higher among males, at 30 percent versus 21.9 percent in the United States and 80 percent versus 73 percent in South Korea.

Treatment options remain constrained. Only two antifibrotic drugs, pirfenidone and nintedanib, hold universal approval. They can safely slow the disease but cannot stop or reverse it, cannot meaningfully stabilize lung function or improve quality of life, and some patients develop drug resistance. Lung transplantation remains the only option that can potentially cure IPF and substantially prolong survival, yet donor shortage, uncertain surgical timing and chronic graft dysfunction limit it; roughly half of recipients experience chronic lung allograft dysfunction within five years of transplant.

At the mechanistic core of the review is telomere biology. Telomeres, the repetitive DNA sequences at chromosome ends, shorten with each cell division, and when they reach a critical threshold the DNA damage response pushes cells into irreversible senescence. Telomere shortening is described as the core pathological basis of IPF. Mutations in telomere maintenance genes such as TERT, TERC and DKC1, whether germline or somatic, weaken the telomerase complex and accelerate shortening. Senescent alveolar epithelial cells then secrete a senescence-associated secretory phenotype including IL-6 and TGF-β, which activates fibroblasts and drives collagen and other extracellular matrix production. Smoking can worsen this through epigenetic mechanisms, including hypermethylation of the POT1 promoter by DNA methyltransferases.

Immune and mucosal defense defects form a second mechanistic cluster. MUC5B is highly expressed in the distal airways and honeycomb cyst regions of IPF lungs, where excessive mucus thickens, slows clearance and hinders removal of harmful particles. The TOLLIP gene acts through Toll-like receptor and TGF-β signaling; its variation makes TLR3 overactive, disrupts immune balance and reduces TOLLIP’s usual inhibition of profibrotic TGF-β signaling. Macrophage polarization is also disturbed, with fibrotic lungs showing reduced alveolar FABP4 macrophages and accumulated interstitial SPP1 macrophages that correlate with poor prognosis, alongside a Th17/Th2 imbalance in T cell subsets.

Matrix remodeling and metabolic stress supply a third cluster. Excess extracellular matrix stiffens lung tissue and alters mechanical cues; PIEZO1 becomes highly expressed in Postn-positive myofibroblasts, and its activation through the PIEZO1-RhoA/ROCK-YAP/TAZ axis drives fibroblast proliferation, with genetic deletion or pharmacological inhibition reducing fibrogenesis in murine models. Mutations in surfactant protein genes SFTPC and SFTPA2 cause protein misfolding and endoplasmic reticulum stress, and a defined pathway links mutant SFTPA1 through ER stress and the IRE1α-JNK axis to RIPK3-MLKL-mediated necroptosis of type II alveolar epithelial cells. Overactive mTOR signaling suppresses autophagy genes and promotes fibroblast activation and collagen production.

On the therapeutic front, the review surveys agents beyond the two approved drugs. The phase III FIBRONEER-IPF trial showed that nerandomilast, a selective PDE4B inhibitor, significantly slowed FVC decline. By contrast, the phase III STARSCAPE trial of zinpentraxin alfa failed to outperform placebo on key endpoints and was terminated early after a prespecified interim futility analysis, with the authors noting that the encouraging phase II signal was driven by outliers in the placebo arm. Pamrevlumab likewise showed promise in phase II but missed its primary endpoint in the phase III ZEPHYRUS-1 trial, with a between-group FVC difference of 70 mL and P = 0.29. The second-generation LPA1 antagonist admilparant slowed lung function decline in phase II and is in global phase III development, while IL-11-targeting and JAK-inhibitor approaches remain at earlier stages requiring further evidence.

Prognostic genetics feature prominently. A two-stage international GWAS identified the intronic PCSK6 variant rs35647788 as a genome-wide significant prognostic locus: it does not raise disease susceptibility but confers a 4.11-fold higher hazard of death or lung transplant and shortens transplant-free survival. A registry cohort of 428 patients with fibrotic interstitial lung diseases validated that this signature is exclusive to IPF, and circulating PCSK6 concentrations positively correlate with quantitative CT fibrosis load. Other markers carry prognostic weight: the TLR variant rs3775291 is associated with accelerated FVC decline and higher death risk (HR = 4.98), TOLLIP rs5743890 TT genotype with susceptibility and high mortality, and TERT rs2736100 with reduced TERT expression, shorter telomeres and poorer pirfenidone response in CA genotype carriers.

The review also stresses gene-environment interaction. Smoking can trigger an accelerated aging mechanism in people carrying TERT mutations, damaging telomeres through oxidative stress and releasing inflammatory genes such as ISG15 and IFN-γ, potentially making genetic risk that would have emerged in old age appear early as severe IPF. MUC5B promoter mutations weaken clearance of smoke and particulates, allowing toxic factors to persist and continually damage alveolar epithelium. Epidemiological studies identify high-risk subgroups, chiefly people aged 60 to 70 and those with long-term exposure to fibrogenic dusts or polluted air; IPF is uncommon under age 50.

Challenges and future directions round out the analysis. GWAS have identified 20 to 30 IPF susceptibility loci, but about 90 percent of significant loci sit in non-coding regions of unknown function, and genetic research remains heavily focused on European-ancestry populations, limiting generalizability; the MUC5B rs35705950 risk allele, for instance, is markedly less frequent in some Asian groups and African Americans, diminishing its predictive power there. Looking forward, the review highlights spatial and single-cell transcriptomics maps of fibrotic lung tissue, liquid biopsy approaches in which an exosomal protein panel achieved an AUC of 0.936 for interstitial lung disease diagnosis and circulating exosomal circular RNAs such as hsa_circ_0044226 reached an AUC of 0.991, and dynamic monitoring through wearables and advanced imaging. Together, the authors argue, these threads point toward genomics-guided precision medicine replacing purely empirical management of IPF.

Subject of Research: A review integrating genetics, multi-omics mechanisms and prognostic risk stratification in idiopathic pulmonary fibrosis.

Article Title: Multi-omics insights into the mechanisms and prognosis of IPF

Article References: Chen, D., Chen, Q., Liu, H., Wang, Z., Liu, X., Hu, J., & Lu, C. (2026). Multi-omics insights into the mechanisms and prognosis of IPF. Genes and Environment, 48(1), Article 16. https://doi.org/10.1186/s41021-026-00364-0

Image Credits: AI Generated

DOI: 10.1186/s41021-026-00364-0

Keywords: idiopathic pulmonary fibrosis, genetics, multi-omics, telomeres, MUC5B, TOLLIP, antifibrotic drugs, clinical trials, gene-environment interaction, multi-gene risk score, precision medicine, lung fibrosis